Merck and Roche form hepatitis C collaboration
Executive Summary
Roche’s Genentech Inc. has agreed to nonexclusively co-promote in the US Merck & Co. Inc.’s newly approved Victrelis (boceprevir) along with peginterferon alfa and ribavirin as a triple therapy for chronic hepatitis C. Presently the standard HCV regimen includes coupling the interferon with ribavirin.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice